Skip to main content

Table 1 Patient characteristics,  n = 40

From: Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

  Aromatase inhibitor ( n  = 28) Trastuzumab ( n  = 12)
   n (%) Median
(min, max)
 n (%) Median
(min, max)
Age, years 58 (35, 83) 48 (38, 71)
Postmenopausal 21 (75%) 9 (75%)
ER positive 28 (100%) 6 (50%)
PgR positive 26 (93%) 6 (50%)
HER2     
Negative 25 (89%) 0 (0%)
Positive 0 (0%) 12 (100%)
Equivocal/not done 3 (11%) 0 (0%)
Disease status     
Newly diagnosed 17 (61%) 5 (42%)
Recurrent 11(39%) 7 (58%)
Disease stage     
Stage I-III (newly diagnosed) 14 (50%) 3 (25%)
Metastatic (newly diagnosed) 3 (11%) 2 (17%)
Metastatic (recurrent, newly stage IV) 5 (18%) 5 (41%)
Metastatic (recurrent stage IV) 6 (21%) 2 (17%)
Histology     
Ductal 14 (50%) 9 (75%)
Lobular 9 (32%) 1 (8%)
Ductal and lobular 2 (7%) 0 (0%)
Unknown 3 (11%) 2 (17%)
PET index lesion     
Breast 16 (57%) 5 (41%)
Nodal/soft tissue 6 (21%) 3 (25%)
Bone 1 (4%) 2 (17%)
Visceral 5 (18%) 2 (17%)